These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 7298112)

  • 21. Evaluation of once daily hydralazine in inadequately controlled hypertension.
    Danielson M; Kjellberg J; Ohman P; Wernersson B
    Acta Med Scand; 1983; 214(5):373-80. PubMed ID: 6362341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of oral hydralazine in chronic heart failure.
    Hanson A; Johansson BW; Wernersson B; Wåhlander LA
    Eur J Clin Pharmacol; 1983; 25(4):467-73. PubMed ID: 6653641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of dose on acetylator phenotype distribution of hydralazine.
    Timbrell JA; Harland SJ; Facchini V
    Clin Pharmacol Ther; 1981 Mar; 29(3):337-43. PubMed ID: 7471604
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polymorphic acetylation of hydralazine.
    Timbrell JA; Harland SJ; Facchini V
    Clin Pharmacol Ther; 1980 Sep; 28(3):350-5. PubMed ID: 7408395
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acetylation phenotype in hypertensive patients.
    Huang CY; Chu JY; Yen TC
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1992 Jan; 8(1):1-5. PubMed ID: 1548734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma hydrazine concentrations in man after isoniazid and hydralazine administration.
    Blair IA; Mansilla Tinoco R; Brodie MJ; Clare RA; Dollery CT; Timbrell JA; Beever IA
    Hum Toxicol; 1985 Mar; 4(2):195-202. PubMed ID: 4007883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of hydralazine, apparent hydralazine and hydralazine pyruvic acid hydrazone in humans.
    Shepherd AM; Ludden TM; Haegele KD; Talseth T; McNay JL
    Res Commun Chem Pathol Pharmacol; 1979 Oct; 26(1):129-44. PubMed ID: 515498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolism of hydralazine in man. Part II: Investigation of features relevant to drug safety.
    Dubois JP; Schmid K; Riess W; Hanson A; Henningsen NC; Andersson OK
    Arzneimittelforschung; 1987 Feb; 37(2):189-93. PubMed ID: 3580022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of acetylator phenotype and renal function on the antihypertensive effect of hydralazine.
    Koopmans PP; Hoefnagels WH; Huysmans FT; Thien T
    Neth J Med; 1984; 27(3):69-73. PubMed ID: 6709112
    [No Abstract]   [Full Text] [Related]  

  • 30. Relationship between the genetically determined acetylator phenotype and DNA damage induced by hydralazine and 2-aminofluorene in cultured rabbit hepatocytes.
    McQueen CA; Maslansky CJ; Glowinski IB; Crescenzi SB; Weber WW; Williams GM
    Proc Natl Acad Sci U S A; 1982 Feb; 79(4):1269-72. PubMed ID: 6951172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the acetylation of procainamide and sulfadimidine in man.
    Frislid K; Berg M; Hansteen V; Lunde PK
    Eur J Clin Pharmacol; 1976 Mar; 09(5-6):433-8. PubMed ID: 971707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hydralazine dose-response curve analysis.
    Graves DA; Muir KT; Richards W; Steiger BW; Chang I; Patel B
    J Pharmacokinet Biopharm; 1990 Aug; 18(4):279-91. PubMed ID: 2231320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hydrallazine and beta-blockade in refractory hypertension with characterization of acetylator phenotype.
    Hunyor SN
    Aust N Z J Med; 1975 Dec; 5(6):530-6. PubMed ID: 7224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship of sulfamethazine disposition kinetics to acetylator phenotype in man. A preliminary study.
    Chapron CJ; Blum MR
    J Clin Pharmacol; 1976 Jul; 16(7):338-44. PubMed ID: 947966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hydralazine-induced lupus: is there a toxic metabolic pathway?
    Timbrell JA; Facchini V; Harland SJ; Mansilla-Tinoco R
    Eur J Clin Pharmacol; 1984; 27(5):555-9. PubMed ID: 6519160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Further evidence for an acetylator phenotype difference in the metabolism of hydralazine in man.
    Facchini V; Timbrell JA
    Br J Clin Pharmacol; 1981 Apr; 11(4):345-51. PubMed ID: 7259927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hydrallazine-induced lupus erythematosus-like syndrome in a patient of the rapid acetylator phenotype.
    Harland SJ; Facchini V; Timbrell JA
    Br Med J; 1980 Jul; 281(6235):273-4. PubMed ID: 7427242
    [No Abstract]   [Full Text] [Related]  

  • 38. Haemodynamic response to intravenous hydralazine in patients with pulmonary hypertension.
    McGoon MD; Seward JB; Vlietstra RE; Choo MH; Moyer TP; Reeder GS
    Br Heart J; 1983 Dec; 50(6):579-85. PubMed ID: 6652000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of alprenolol and hydralazine on plasma renin concentration in patients with arterial hypertension.
    Pedersen EB; Kornerup HJ
    Acta Med Scand; 1975 Nov; 198(5):379-83. PubMed ID: 1199814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective high-performance liquid chromatographic assays for hydralazine and its metabolites in plasma of man.
    Reece PA; Cozamanis I; Zacest R
    J Chromatogr; 1980 Mar; 181(3-4):427-40. PubMed ID: 7391156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.